Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

23 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Paricalcitol Articles

Abbott Labs beats consensus forecasts with 40% EPS rise on strong drug sales

18 July 2005

Abbott UK: "growth of 70% in next five years"

27 June 2005

Abbott files NDA for Zemplar capsules

9 August 2004

Abbott to study D-receptor activation in chronic kidney disease

24 November 2003

US FDA makes progress, says their own product review record for 1998

29 January 1999

Quality, not quantity, sums up New Chemical Entity launches in 1998

7 January 1999

Tetrionics to Manufacture Paricalcitrol For Abbott's Zemplar

19 November 1998

Canadian Filing For One-Alpha D2

6 August 1998

Abbott's Paricalcitol Is Approved In The USA

30 April 1998

Showing 1-9 of 9 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS